Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IMT 504

Drug Profile

IMT 504

Alternative Names: IMT504

Latest Information Update: 05 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Immunotech SA
  • Class Oligodeoxyribonucleotides
  • Mechanism of Action B cell stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus
  • No development reported Breast cancer; Chronic lymphocytic leukaemia; Hepatitis B; Influenza virus infections; Neuropathic pain; Osteoporosis; Rabies; Sepsis

Most Recent Events

  • 01 Apr 2017 Preclinical trials in Diabetes mellitus in Argentina (Parenteral)
  • 01 Apr 2017 Pharmacodynamics data from a preclinical study in Diabetes mellitus presented at the the 99th Annual Meeting of the Endocrine Society (ENDO 2017)
  • 10 Jul 2008 IMT 504 is available for licensing (http://www.immunotech-sa.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top